November 12, 1985

Clinger Hayes

Coats Hefner

Cobey Heftel

Coble Hendon

Coelho Henry

Coleman (MO) Hertel

Coleman (TX) Hiler

Collins Hillis

Combest Holt

Conte Hopkins

Conyers Horton

Cooper Howard

Coughlin Hoyer

Courter Hubbard

Coyne Hughes

Craig Hutto

Crane Hyde

Daniel Ireland

Dannemeyer Jacobs

Darden Jeff ords

Daub Jenkins

Davis Johnson

de Ia Garza Jones (NC)

DeLay Jones (OK)

Dellums Jones (TN)

Derrick Kanjorski

DeWine Kaptur

Dickinson Kauich

Dicks Kastenmeler

Dingell Kemp

DioGuardi Kennelly

Dixon Kildee

Donnelly Kleczka

Dorgan (ND) Kolbe

Dornan (CA) Kolter

Dowdy Kostmayer

Downey Kramer

Dreier LaFalce

Duncan Lagomarsino

Durbin Lantos

Dwyer Latta

Dymally Leach (IA)

Dyson Leath (TX)

Early Lehman (CA)

Eckart (OH) Lehman (FL)

Eckert (NY) Leland

Edwards (CA) Lent

Edwards (OK) Levin (MI)

Emerson Levine (CA)

English Lewis (CA) Erdreich Lewis (FL)

Evans (IA) Lightfoot

Evans (IL) Lpinski Fascell Livingston

Fawell Lloyd

Fazio Loeffler

Felghan Long

Fiedler Lott

Fields Lowery (CA) Fish Lowry (WA)

Flippo LuJan

Florio Luken

Foglletta Lundine

Foley Lungren

Ford (MI) Mack

Ford (TN) MacKay

Frank Madigan

Franklin Manton

Frenzel Markey

Frost Marlenee

Fuqua Martin (IL)

Gallo Martin (NY) Garcia Martinez

Gaydos Matsui

GeJdenson Mavroules

Gekas Mazzoli

Gephardt McCain

Gilman McCloskey

Glickman McCollum

Gonzalez McCurdy

Goodling MeDade

Gordon McEwen

Gradison McGrath

Gray (PA) McHugh

Green McKernan

Gregg McMillan

Grotberg Meyers

Guarlni Michel

Gunderson Mikulskl

Hall (OH) Miller (CA) Hall, Ralph Miller (OH)

Hamilton Miller (WA)

Hammerschmidt Mineta

Hansen Mitchell

Hatcher Moakley Hawkins Molinari

CONGRESSIONAL RECORD-HOUSE

Mollohan

Monson

Montgomery

Moody

Moore

Moorhead

Morrison (CT)

Morrison (WA)

Mraszek

Murphy

Murtha

Natcher

Neal

Nelson

Nichols

Nielson

Nowak

Oakar

Oberstar

Obey

Olin

Ortiz

Owens

Oxley

Packard

Panetta

Parris

Pease

Penny

Pepper

Perkins

Petri

Fickle

Porter

Price

Pursell

Quillen

Rahall

Rangel

Ray

Regula

Reid

Richardson

Ridge

Rinaldo

Ritter

Roberts

Robinson

Rodino

Roe

Roemer

Rogers

Rose

Rostenkowski

Roukema

Rowland (CT)

Rowland (GA)

Roybal

Rudd

Russo

Sabo

Savage

Saxton

Schaefer

Scheuer

Schneider

Schroeder

Schuette

Schulze

Schumer

Selberling

Sensenbrenner

Sharp

Shaw

Shelby

Shumway

Shuster

Sikorski

Sllander

Slsisky

Skeen

Skelton

Slattery

Slaughter

Smith (FL) Smith (IA)

Smith (NE)

Smith (NJ)

Smith, Denny

(OR)

Smith, Robert

(NH)

Smith, Robert

(OR)

Snowe

Snyder

Solarz

Solomon

Spence

Spratt

St Germain

Staggers

Stallings

Stangeland

Stark

Stenholm

Stokes

Strang

Stratton

Studds

Stump

Sundquist

Swift

Swindall

Synar

Tallon

Tauke

Tauzin

Taylor

Thomas (CA)

Thomas (GA)

Torres

Towns

Traficant

Traxler

Udall

Valentine

Vander Jagt

Vento

Vlsclosky

Volkmer

Vucanovich

Walgren

Walker

Watkins

Waxman

Weaver

Weber

Weiss

Wheat

Whitehurst

Whitley

Whittaker

Whitten

Williams

Wilson

Wirth

Wise

Wolf

Wolpe

Wortley

Wright

Wyden

Wylie

Yates

Yatron

Young (AK) Young (MO) Zschau

NAYS-3

Crockett Myers Young (FL)

NOT VOTING-26

Addabbo Edgar McCandless

Boland Fowler McKinney Bonker Gibbons Mica

Bosco Gingrich O'Brien

Breaux Gray (IL) Pashayan Brown (CA) Hartnett Roth

Chandler Huckaby Sweeney Chapple Hunter Torricelli

Daschle Kindness

D 1510

Mr. CROCKETT changed his vote

from "yea" to "nay."

Mr. REID changed his vote from

"nay" to "yea." So (two-thirds having voted in favor

thereof) the rules were suspended and

the resolution, as amended, was agreed

to.

The result of the vote was announced as above recorded.

The title of the resolution was

amended so as to read: "Resolution expressing the sense of the House of

Representatives that the President

should pursue an active and impartial investigation to determine whether

Miroslav Medvid was accorded all the

rights due him as a potential defector."

A motion to reconsider was laid on

the table.

COMMUNICATION FROM THE

CLERK OF THE HOUSE

The SPEAKER pro tempore laid

before the House the following communication from the Clerk of the

House of Representatives:

WASHINOTON, DC.,

November 8, 1985.

Hon. THOMAs P. O'NzILL, Jr,,

The Speaker, House of Representative.,

Washington, DC.

DEAR MR. SPEAKER: Pursuant to the per.

mission granted in Clause 5, Rule III of the

Rules of the U.S. House of Representatives,

I have the honor to transmit sealed enve- lopes received from the White House at 4:35

p.m. on Friday, November 8, 1985 as follows:

(1) Said to contain a message from the

President wherein he transmits the 1983

and 1984 annual reports under the Federal

Mine Safety and Health Act of 1977 as prepared by the Secretary of Labor; and

(2) Said to contain a message from the

President whereby he transmits the 1984

31379

annual reports on activities under the Occupational Safety and Health Act of 1970 of

the Departments of Labor and Health and

Human Services and of the Occupational

Safety Review Commission; and

(3) Said to contain H.R. 2409. an Act to

amend the Public Health Service Act to

revise and extend the authorities under that

Act relating to the National Institutes of

Health and National Research Institutes,

and for other purposes, and a veto message

thereon.

With kind regards, I am,

Sincerely,

BENJAMIN J. GUTHRIE,

Clerk House of Representatives.

ANNUAL REPORTS FOR FISCAL

YEARS 1983 and 1984 ON MINE

SAFETY AND HEALTH ACTIVITIES-MESSAGE FROM THE

PRESIDENT OF THE UNITED

STATES

The SPEAKER pro tempore laid

before the House the following message from the President of the United

States; which was read and, together with the accompanying papers, without objection, referred to the Committee on Education and Labor:

(For message, see proceedings of the

Senate of today, Tuesday, November

12, 1985.)

0 1520

ANNUAL REPORTS OF DEPARTMENT OF LABOR, DEPARTMENT OF HEALTH AND HUMAN

SERVICES, AND OF OCCUPATIONAL SAFETY AND REVIEW

COMMISSION-MESSAGE FROM

THE PRESIDENT OF THE

UNITED STATES

The SPEAKER pro tempore laid

before the House the following message from the President of the United

States; which was read and, together with the accompanying papers, without objection, referred to the Committee on Education and Labor:

(For message, see proceedings of the

Senate of today, Tuesday, November

12, 1985.)

HEALTH RESEARCH EXTENSION

ACT OF 1985-VETO MESSAGE

FROM THE PRESIDENT OF THE

UNITED STATES

The SPEAKER pro tempore laid

before the House the following veto

message from the President of the

United States:

To the House of Representatives: I am returning herewith without my

approval H.R. 2409, the "Health Research Extension Act of 1985," which

would extend and amend the biomedical research authorities of the National Institutes of Health (NIH).

My action on this bill should in no

way be interpreted as a lessening of

this Administration's strong commit-
CONGRESSIONAL RECORD-HOUSE

ment to the biomedical resea ch endeavors of NIH. In fact, I want to underscore my personal support and the

support of my Administration for biomedical research and for the NIH. For

over 40 years, the NIH has enjoyed un- paralleled success. Enormous progress

in research and the improved health

of the American people attest to that

success. An appropriations bill or a continuing resolution will provide uninterrupted funding for NIH activities

in fiscal year 1986.

I believe that instead of fostering a

strong Federal biomedical research

effort, H.R. 2409 would adversely

affect the pursuit of research excellence at NIH by:

-imposing numerous administrative

and program requirements that

would interfere with the ability to

carry forward our biomedical research activities in the most costeffective manner and would misallocate scarce financial and personnel resources;

-establishing unneeded new organizations, which would lead to un- necessary coordination problems

and administrative expenses while

doing little to assist the biomedical

research endeavors of NIH; and

-imposing a uniform set of authorities on all the research institutes,

thus diminishing our administrative flexibility to respond to changing biomedical research needs.

Although H.R. 2409 is overloaded

with objectionable provisions that seriously undermine and threaten the

ability of NIH to manage itself and is

therefore unacceptable, I recognize

there are areas in which the administration can step forward to strengthen

specific research efforts.

As Senator HATCH pointed out when

introducing the NIH reauthorization

bill in the Senate in June of this year,

arthritis afflicts some 49 million of

this Nation's citizens and "all of us

suffer, at some time in our life, from some form of arthritis." Further, ar- thritis, along with musculoskeletal and

skin diseases, "collectively result in an extraordinary loss to our economy

from lost productivity as well as from

medical expense."

In recognition of the plight of the

millions of arthritis victims and society's costs, I have directed the Secretary of Health and Human Services to

establish administratively a separate

National Institute of Arthritis and

Musculoskeletal and Skin Diseases

that will meet the continuing need for

coordinated research in this important

area. This directive is consistent with

the Department's recommendation to me that this Institute be established.

At the same time, I do not believe

that the establishment of a nursing research center at NIH is appropriate,

for a very basic reason-there is a lack

of compatibility between the mission

of such a center and the mission of

NIH. The biomedical research activities of NIH are concerned with discovering the etiology of and treatment for

diseases. In contrast, nursing research uses substantive scientific information

and methodology and focuses on their

relevance to nursing practice and administration. This research is important, but neither it nor disease-oriented research are served by the provisions of the bill.

H.R. 2409 manifests an effort to

exert undue political control over decisions regarding scientific research,

thus limiting the ability of the NIH to

set this Nation's biomedical research

agenda. I do not believe that it is

either necessary or wise to restrict the

flexibility under which the NIH has

operated so successfully. In 1984, I rejected a very similar bill, and once again I find no reasonable Justification

for the extensive changes to the NIH

mandated by H.R. 2409. In order to

allow NIH to continue to provide excellence in biomedical research and in

its management, I am disapproving

this bill.

RONALD REAGAN.

THE WHITE HOUSE, November 8, 1985.

The SPEAKER pro tempore. The

objections of the President will be

spread at large upon the Journal.

The question is, Will the House, on

reconsideration, pass the bill, the obJections of the President to the con- trary notwithstanding?

The gentleman from California [Mr.

WAXMAN] is recognized for 1 hour.

Mr. WAXMAN. Mr. Speaker, first of

all, I yield 30 minutes of my time to be

managed by the ranking Republican

member of our subcommittee, the gen- tleman from Illinois [Mr. MADIGAN],

pending which I yield myself such

time as I may consume. Mr. Speaker; this afternoon we will

have the opportunity to reassert con- gressional and public support for a strong and viable biomedical research

effort by overriding the President's

veto of H.R. 2409.

The purpose of the Health Research

Extension Act was to preserve America's preeminence in medical research.

It represented a bipartisan compromise resulting from 3 years of consideration between the House and

Senate. It was the product of countless

hearings and markup sessions.

The National Institutes of Health is

a national treasure. It has done more to expand human knowledge about

the cause, treatment, and prevention

of disease than any other research institution in the world. It has accom- plished these successes because of the

responsible guidance and oversight of

the Congress.

On October 23, this House approved

the conference report on H.R. 2409 by an overwhelming vote of 395 to 10.

The Senate passed the legislation

unanimously. Last Friday, November

8, the President vetoed this legislation.

I regret the President's action.

Today we will have the opportunity

to let the administration know that

this Congress intends to stand behind

this legislation and support one of this

Nation's proudest achievements, its

world leadership in biomedical research.

H.R. 2409 represents a responsible

balance between scientific freedom

and the Congress' responsibility to

oversee the $5 billion annual budget of

the National Institutes of Health. This

legislation is needed to keep biomedical research on a firm and balanced

foundation. It represents a necessary

and forceful statement of support for

the biomedical research programs of

the NIH.

Mr. Speaker, let me briefly summarize some of the major provisions of

the legislation. H.R. 2409 would:

Reauthorize the National Cancer

Act and continue the war on cancer

for 3 years.

Establish a new National Institute of

Arthritis and Musculoskeletal and

Skin Diseases.

Emphasize patient care research

through a new National Center for

Nursing Research.

Consolidate unnecessary reporting

requirements.

Establish high priorities for research

on Aizheimer's disease, spinal cord

injury, AIDS and other public health

emergencies.

Emphasize health promotion and

disease prevention.

Reauthorize the National Heart,

Lung and Blood Institute for three

years.

Place a ceiling on administrative

costs at the NIH.

Establish procedures for dealing

with scientific fraud.

Establish guidelines for the proper care and treatment of animals used in

biomedical research.

Mr. Speaker, support for biomedical

research is an investment in the

future. I urge Members to join in

maintaining the quality and productivity of biomedical research by supporting the Health Research Extension

Act of 1985.

01 1530

Let me point out a couple of considerations in overriding this veto.

The dispute with those who have

been successful in urging the President to veto the bill was not one over

money. The dispute was over whether

the Congress ought to have a say in some of these issues that are dealt

with at NIH.

We feel that if the taxpayers' dollars, $5 billion a year, are being used

for biomedical research, we ought to

spell out some of our priorities. We

ought to tell NIH what we think they

ought to be looking at. It is not for us

to make the individual decisions that

31380 November 12, 1985